QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
Log in
OTCMKTS:ALPMY

Astellas Pharma Stock Forecast, Price & News

$13.63
-0.14 (-1.02 %)
(As of 10/28/2020 12:00 AM ET)
Add
Compare
Today's Range
$13.41
Now: $13.63
$13.71
50-Day Range
$13.77
MA: $14.69
$15.45
52-Week Range
$12.48
Now: $13.63
$18.43
Volume91,122 shs
Average Volume85,759 shs
Market Capitalization$25.38 billion
P/E Ratio14.20
Dividend Yield1.96%
Beta0.67
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. It offers XTANDI, an androgen receptor signaling inhibitor for the treatment of prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ transplant rejection. The company also provides Vesicare for OAB treatment; Eligard for prostate cancer treatment; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical collaboration agreement with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and Cytokinetics, Incorporated, as well as an agreement with BANDAI NAMCO Entertainment Inc. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Read More
Astellas Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ALPMY
CUSIPN/A
CIKN/A
Phone813-3244-3000
Employees15,883

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.97 billion
Cash Flow$1.23 per share
Book Value$6.28 per share

Profitability

Miscellaneous

Outstanding Shares1,861,790,000
Market Cap$25.38 billion
Next Earnings DateN/A
OptionableNot Optionable
$13.63
-0.14 (-1.02 %)
(As of 10/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Astellas Pharma (OTCMKTS:ALPMY) Frequently Asked Questions

How has Astellas Pharma's stock been impacted by Coronavirus?

Astellas Pharma's stock was trading at $15.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALPMY shares have decreased by 13.3% and is now trading at $13.63.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Astellas Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Astellas Pharma
.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its earnings results on Tuesday, August, 4th. The company reported $0.25 earnings per share for the quarter. The firm earned $2.85 billion during the quarter.
View Astellas Pharma's earnings history
.

When did Astellas Pharma's stock split? How did Astellas Pharma's stock split work?

Astellas Pharma shares split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of Astellas Pharma stock prior to the split would have 125 shares after the split.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a increase in short interest in September. As of September 30th, there was short interest totaling 9,900 shares, an increase of 125.0% from the September 15th total of 4,400 shares. Based on an average trading volume of 121,900 shares, the days-to-cover ratio is presently 0.1 days.
View Astellas Pharma's Short Interest
.

Who are some of Astellas Pharma's key competitors?

Who are Astellas Pharma's key executives?

Astellas Pharma's management team includes the following people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Representative Director (Age 60)
  • Mr. Naoki Okamura, Exec. VP, CFO & Representative Director
  • Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.
  • Ms. Linda Friedman, Gen. Counsel & VP
  • Mr. Stig Ogata, VP of Corp. Communications

What is Astellas Pharma's stock symbol?

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

How do I buy shares of Astellas Pharma?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Astellas Pharma's stock price today?

One share of ALPMY stock can currently be purchased for approximately $13.63.

How big of a company is Astellas Pharma?

Astellas Pharma has a market capitalization of $25.38 billion and generates $11.97 billion in revenue each year. The company earns $1.80 billion in net income (profit) each year or $0.96 on an earnings per share basis. Astellas Pharma employs 15,883 workers across the globe.

What is Astellas Pharma's official website?

The official website for Astellas Pharma is www.astellas.com.

How can I contact Astellas Pharma?

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.

This page was last updated on 10/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.